Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Tingting Zhang; Weiwei Tian; Shuang Wei; Xinyi Lu; Jing An; Shaolong He; Jie Zhao; Zhilin Gao; Li Li; Ke Lian; Qiang Zhou; Huilai Zhang; Liang Wang; Liping Su; Huicong Kang; Ting Niu; Ailin Zhao; Jing Pan; Qingqing Cai; Zhenshu Xu; Wenming Chen; Hongmei Jing; Peng Li; Wanhong Zhao; Yang Cao; Jianqing Mi; Tao Chen; Yuan Chen; Ping Zou; Veronika Lukacs-Kornek; Christian Kurts; Jian Li; Xiansheng Liu; Qi Mei; Yicheng Zhang; Jia Wei

doi:10.1186/s40164-023-00426-x

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Tingting Zhang
, Weiwei Tian
, Shuang Wei
, Xinyi Lu
, Jing An
, Shaolong He
, Jie Zhao
, Zhilin Gao
, Li Li
, Ke Lian
, Qiang Zhou
, Huilai Zhang
, Liang Wang
, Liping Su
, Huicong Kang
, Ting Niu
, Ailin Zhao
, Jing Pan
, Qingqing Cai
, Zhenshu Xu

Wenming Chen, Hongmei Jing, Peng Li, Wanhong Zhao, Yang Cao, Jianqing Mi, Tao Chen, Yuan Chen, Ping Zou, Veronika Lukacs-Kornek, Christian Kurts, Jian Li, Xiansheng Liu, Qi Mei, Yicheng Zhang, Jia Wei

Shanxi Medical University
Huazhong University of Science and Technology
Shanxi Bethune Hospital
Tianjin Medical University
Capital Medical University
Sichuan University
Beijing GoBroad Boren Hospital
Sun Yat-Sen University Cancer Center
Fujian Medical University
Peking University
CAS - Guangzhou Institute of Biomedicine and Health
The Second Affiliated Hospital of Xi'an Jiaotong University
Immunotherapy Research Center for Hematologic Diseases of Hubei Province
Shanghai Jiao Tong University
University of Bonn

科研成果: 期刊稿件 › 文献综述 › 同行评审

12 引用（Scopus）

摘要

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

源语言	英语
期刊论文编号	66
期刊	Experimental Hematology and Oncology
卷	12
期	1
DOI	https://doi.org/10.1186/s40164-023-00426-x
出版状态	已出版 - 12月 2023
已对外发布	是

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

可持续发展目标 3 良好健康与福祉

访问文件

10.1186/s40164-023-00426-x

其它文件与链接

链接到 Scopus 的出版物

引用此

Zhang, T., Tian, W., Wei, S., Lu, X., An, J., He, S., Zhao, J., Gao, Z., Li, L., Lian, K., Zhou, Q., Zhang, H., Wang, L., Su, L., Kang, H., Niu, T., Zhao, A., Pan, J., Cai, Q., ... Wei, J. (2023). Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Experimental Hematology and Oncology, 12(1), 期刊论文 66. https://doi.org/10.1186/s40164-023-00426-x

@article{fd568742447f4f5ab303f461ef633442,

title = "Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era",

abstract = "The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.",

keywords = "CAR T-cell, COVID-19, Hematological malignancies, Recommendations, SARS-CoV-2, Treatment",

author = "Tingting Zhang and Weiwei Tian and Shuang Wei and Xinyi Lu and Jing An and Shaolong He and Jie Zhao and Zhilin Gao and Li Li and Ke Lian and Qiang Zhou and Huilai Zhang and Liang Wang and Liping Su and Huicong Kang and Ting Niu and Ailin Zhao and Jing Pan and Qingqing Cai and Zhenshu Xu and Wenming Chen and Hongmei Jing and Peng Li and Wanhong Zhao and Yang Cao and Jianqing Mi and Tao Chen and Yuan Chen and Ping Zou and Veronika Lukacs-Kornek and Christian Kurts and Jian Li and Xiansheng Liu and Qi Mei and Yicheng Zhang and Jia Wei",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1186/s40164-023-00426-x",

language = "英语",

volume = "12",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central Ltd",

number = "1",

}

Zhang, T, Tian, W, Wei, S, Lu, X, An, J, He, S, Zhao, J, Gao, Z, Li, L, Lian, K, Zhou, Q, Zhang, H, Wang, L, Su, L, Kang, H, Niu, T, Zhao, A, Pan, J, Cai, Q, Xu, Z, Chen, W, Jing, H, Li, P, Zhao, W, Cao, Y, Mi, J, Chen, T, Chen, Y, Zou, P, Lukacs-Kornek, V, Kurts, C, Li, J, Liu, X, Mei, Q, Zhang, Y & Wei, J 2023, 'Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era', Experimental Hematology and Oncology, 卷 12, 号码 1, 66. https://doi.org/10.1186/s40164-023-00426-x

TY - JOUR

T1 - Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

AU - Zhang, Tingting

AU - Tian, Weiwei

AU - Wei, Shuang

AU - Lu, Xinyi

AU - An, Jing

AU - He, Shaolong

AU - Zhao, Jie

AU - Gao, Zhilin

AU - Li, Li

AU - Lian, Ke

AU - Zhou, Qiang

AU - Zhang, Huilai

AU - Wang, Liang

AU - Su, Liping

AU - Kang, Huicong

AU - Niu, Ting

AU - Zhao, Ailin

AU - Pan, Jing

AU - Cai, Qingqing

AU - Xu, Zhenshu

AU - Chen, Wenming

AU - Jing, Hongmei

AU - Li, Peng

AU - Zhao, Wanhong

AU - Cao, Yang

AU - Mi, Jianqing

AU - Chen, Tao

AU - Chen, Yuan

AU - Zou, Ping

AU - Lukacs-Kornek, Veronika

AU - Kurts, Christian

AU - Li, Jian

AU - Liu, Xiansheng

AU - Mei, Qi

AU - Zhang, Yicheng

AU - Wei, Jia

PY - 2023/12

Y1 - 2023/12

N2 - The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

AB - The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

KW - CAR T-cell

KW - COVID-19

KW - Hematological malignancies

KW - Recommendations

KW - SARS-CoV-2

KW - Treatment

UR - https://www.scopus.com/pages/publications/85165941915

U2 - 10.1186/s40164-023-00426-x

DO - 10.1186/s40164-023-00426-x

M3 - 文献综述

AN - SCOPUS:85165941915

SN - 2162-3619

VL - 12

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

IS - 1

M1 - 66

ER -

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

摘要

联合国可持续发展目标

访问文件

其它文件与链接

学术指纹

引用此